Antibody Drug Conjugate market Trends, Analysis by 2035

The potential of antibody drug conjugates for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical sector. Specifically, the success of these products can be attributed to their ability to effectively identify and eliminate diseas

  • Notice: Undefined index: share_to in /var/www/ on line 41

The financial opportunity within the antibody drug conjugate market has been analyzed across the following segments:


  • Target Disease Indication
  • Acute Lymphoblastic Leukemia
  • Breast Cancer
  • B-Cell Lymphoma
  • Cervical Cancer
  • Gastric Cancer
  • Lung Cancer
  • Multiple Myeloma
  • Renal Cancer
  • Other Target Disease Indications


  • Therapeutic Area
  • Hematological Cancer
  • Solid Tumor


  • Linker
  • Hydrazone (4-(4-Acetylphenoxy) Butanoic Acid (Acbut)
  • Maleimide
  • Maleimidocaproyl
  • Succinimidyl-4-(N-Maleimidomethyl) Cyclohexane-1-Carboxylate
  • Tetrapeptide-Based Linker
  • Valine-Alanine
  • Valine-Citrulline
  • Other Linkers


  • Payload
  • DM1
  • DM4
  • Duocarmycin
  • Monomethyl auristatin E (MMAE)
  • Monomethyl auristatin F (MMAF)
  • Ozogamicin
  • SG3199
  • SN-38 / Irinotecan
  • Other Payloads


  • Target Antigen
  • CD19
  • CD22
  • CD30
  • CD79b
  • HER-2 (ERBB2)
  • Nectin 4
  • Tissue factor
  • TROP-2
  • Other Target Antigen


  • Key Geographical Regions
  • North America
  • Europe
  • Asia-Pacific and Rest of the World


The Antibody Drug Conjugate Market (7th Edition), 2023-2035 report features the following companies, which we identified to be key players in this domain:

  • ADC Therapeutics
  • Astellas Pharma
  • AstraZeneca
  • Byondis
  • Daiichi Sankyo
  • Genentech
  • Gilead Sciences
  • ImmunoGen
  • Pfizer
  • RemeGen


Table of Contents


  1. Preface

    2. Executive Summary

  2. Introduction
  3. Market Landscape


  1. Target Competitiveness Analysis
  2. Company and Drug Profiles
  3. Clinical Trial Analysis
  4. Key Opinion Leaders
  5. Combination Therapies
  6. Partnerships and Collaborations


  1. Funding and Investment Analysis
  2. Patent Analysis


  1. Academic Grants Analysis


  1. Key Commercialization Strategies


  1. Promotional Analysis


  1. Success Protocol Analysis


  1. Novel Conjugation and Linker Technology Platforms


  1. Assessment of Non-Clinical Data First in Human Dosing


  1. Cost Price Analysis


  1. Case Study 1: Contract Manufacturing of Antibody-Drug Conjugates


  1. Case Study 2: Companion Diagnostics for Antibody-Drug Conjugate Therapeutics


  1. SWOT Analysis
  2. Market Sizing and Opportunity Analysis


  1. Executive Insights


  1. Conclusion


  1. Appendix 1: Tabulated Data


  1. Appendix 2: List of Companies and Organizations


To view more details on this report, click on the link:


Learn from experts:  do you know about these emerging industry trends?

Digital Therapies: The “Digital Pills” of current generation

Medical Device Coatings and Modification Technologies


Learn from our recently published whitepaper: -

Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation


About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.


Learn more about Roots Analysis consulting services: 

Roots Analysis Consulting - the preferred research partner for global firms



Ben Johnson

+1 (415) 800 3415





Read more

Warning: mysqli_query(): (HY000/1114): The table '/tmp/#sql_4ae7_0' is full in /var/www/ on line 1160

Warning: mysqli_fetch_assoc() expects parameter 1 to be mysqli_result, bool given in /var/www/ on line 1162